ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,313.00
0.33%
Gold vs US Dollar
2,658.34
0.00%
Brent Oil
72.01
0.00%
Bitcoin
65,742.88
-0.20%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Innate Pharma SA (IPHA) Share Price

IPHA Innate Pharma SA

2.20
0.05 (2.33%)
27 Sep 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Innate Pharma SA NASDAQ:IPHA NASDAQ Depository Receipt  Sponsored ADS France
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.05 2.33 2.20 1.89 3.00 2.21 2.165 2.17 3,034 20:29:56   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 61.64M -7.57M -0.0941 -21.36 172.97M
 Type  Size  Price  Time  Units 
 13 28 2.20 20:00:00 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore IPHA News
23/09/202411:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
23/09/202406:00BWInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
23/09/202406:00BWInnate Pharma reçoit l’autorisation de l’agence américaine du médicament d’initier le développement clinique d’IPH4502, son ADC ciblant Nectine-4, dans les tumeurs solides
12/09/202411:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
12/09/202411:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
12/09/202411:04IHMARKETNEWSU.S. Index Futures Climb Ahead of Key Economic Data Releases; Oil Prices Rise
12/09/202406:00BWInnate Pharma Reports First Half 2024 Business Update and Financial Results
Period
Draw mode
Data Downloads for IPHA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Innate Pharma SA Articles